The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in iRobot To Contact Him Directly To Discuss Their Options

GSAT doubles its Alcazar Teleport footprint in Spain, boosting satellite network resilience across Europe.

DG offers $1 deals, educator discounts and app-based savings to win over budget-savvy back-to-school shoppers.

June brought with it a flurry of ETF launches, doubling May's muted numbers. While many funds expanded on existing trends such as the growth of active management or single-stock exposures, three ETF strategies stand out, bringing something interesting to the table for investors.

The tax exempt status of municipal bonds could be in jeopardy as Congress mulls over whether to tax the income from these debt issues. In the meantime, Vanguard has eight ETFs to contemplate when looking to attain muni exposure.

I reiterate my Buy rating on ASML Holding N.V., expecting another earnings beat driven by strong AI demand and the company's monopoly in EUV lithography. Sustained, robust demand across the AI ecosystem ensures continued need for ASML's monopoly-like EUV technology, signaling strong future orders and a positive management outlook. ASML's seemingly high valuation is justified by its competitive moat, superior growth, and record margins, while still trading at a discount to historical averages.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In 3D Systems To Contact Him Directly To Discuss Their Options

Ford (NYSE: F) has made a name for itself as the recall leader of the car industry.

BP PLC (LSE:BP.) shares rose 2% in afternoon trading after the energy group indicated that its second-quarter numbers and outlook were less bleak than many had feared, despite continued underperformance.

Kura Sushi delivered a strong Q3 double beat, with 17% revenue growth and a surprise profit, validating my earlier bullish call near $50 support. The company is executing well on its debt-free, high-growth model, expanding units over 20% year-over-year and managing costs despite macro headwinds. Same-store sales are still negative but improving sequentially, and new initiatives plus a robust IP calendar should drive further gains into FY 2026.

Investors need to pay close attention to FFIC stock based on the movements in the options market lately.

PepsiCo's near-term results are pressured by FX, tariffs, and capex, but underlying operations and international demand remain solid. Volume growth is the key catalyst for stabilizing the stock and supporting long-term FCF and dividend growth as capex normalizes. The current P/FCF multiple offers an attractive risk-reward opportunity for long-term investors. A return to growth could provide market-beating total returns.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Organon To Contact Him Directly To Discuss Their Options

TEVA stock jumps 21.6% in three months on branded drug growth, biosimilar launches, and margin-boosting cost cuts.

Investors need to pay close attention to Braze stock based on the movements in the options market lately.

– Absence of neurotoxicity of any grade in low-volume disease to-date – – On track for first Biologics License Application (BLA) approved cell therapy in orphan indication relapsed/refractory AL Amyloidosis – – Potential future indication expansion planned – LOS ANGELES, July 11, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced a class-leading safety profile for sterically-optimized CAR-T NXC-201, including absence of neurotoxicity of any grade in low-volume disease to-date, laying a foundation for potential future indication expansion. “We …

AI semiconductor giant Broadcom NASDAQ: AVGO recently found its biggest bull on Wall Street yet. On June 24, analysts at HSBC issued a massive $400 price target on the stock.

This isn't a buy list. It's a shortlist to help you speed up your research. We've included both U.S. and Canadian names, organized by country. Each company comes with a business summary, plus a bull and bear case to help you assess the fit. Comcast benefits from diversified cash flow through broadband, content creation, and international operations. The business remains cyclical—recessions hit industrial demand, and European expansion poses integration risks. Brand power and wide distribution provide resilience. PepsiCo is expanding its healthier product lines and boosting e-commerce. The shift toward healthier foods poses a threat to legacy products.

Jim Wyckoff has spent over 25 years involved with the stock, financial and commodity markets. He was a financial journalist with the FWN newswire service for many years, including stints as a reporter on the rough-and-tumble commodity futures trading floors in Chicago and New York.